1st Jul 2025 11:48
1 July 2025
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Funding Update
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, provides an update on its funding position.
Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.
Enquiries:
|
|
Celadon Pharmaceuticals Plc |
|
James Short | Via Canaccord Genuity Limited |
Canaccord Genuity Limited (Nominated Adviser and Broker) | |
Bobbie Hilliam / Andrew Potts
| +44 (0)20 7523 8000
|
Global Investment Strategy UK Limited (Joint Broker) | +44 (0)20 7048 9400 |
James Sheehan |
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.
Related Shares:
Celadon Pharmaceuticals